Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis
- 1 July 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 13 (7) , 7556-7567
Abstract
Bone metastasis, a clinical complication of patients with advanced breast cancer, seriously reduces the quality of life. To avoid destruction of the bone matrix, current treatments focus on inhibiting the cancer cell growth and the osteoclast activity through combination therapy. Therefore, it could be beneficial to develop a bone-targeted drug delivery system to treat bone metastasis. Here, a bone-targeted nanoplatform was developed using gold nanorods enclosed inside mesoporous silica nanoparticles ([email protected]) which were then conjugated with zoledronic acid (ZOL). The nanoparticles ([email protected]) not only showed bone-targeting ability in vivo but also inhibited the formation of osteoclast-like cells and promoted osteoblast differentiation in vitro. The combination of [email protected] and photothermal therapy (PTT), triggered by near-infrared irradiation, inhibited tumor growth both in vitro and in vivo and relieved pain and bone resorption in vivo by inducing apoptosis in cancer cells and improving the bone microenvironment. This single nanoplatform combines ZOL and PTT to provide an exciting strategy for treating breast cancer bone metastasis.Keywords
Funding Information
- Natural Science Foundation of Hebei Province (B2017201135, B2017201226)
- National Natural Science Foundation of China (31500812, 21807023, 31470961)
- Basic Research Foundation of Education Ministry of Hebei Province (QN2018010)
This publication has 48 references indexed in Scilit:
- Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapyNanoscale, 2018
- Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin ReleaseACS Nano, 2017
- Bone-Targeted Mesoporous Silica Nanocarrier Anchored by Zoledronate for Cancer Bone MetastasisLangmuir, 2016
- Role of bone-anabolic agents in the treatment of breast cancer bone metastasesBreast Cancer Research, 2014
- Skeletal metastasis: treatments, mouse models, and the Wnt signalingChinese Journal of Cancer, 2013
- Bone metastasis targeting: A novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with DocetaxelJournal of Controlled Release, 2012
- Evolving Data about Subtrochanteric Fractures and BisphosphonatesNew England Journal of Medicine, 2010
- Osteoclast‐targeting small molecules for the treatment of neoplastic bone metastasesCancer Science, 2009
- Giant Osteoclast Formation and Long-Term Oral Bisphosphonate TherapyNew England Journal of Medicine, 2009
- Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone MetastasesThe Journal of Clinical Pharmacology, 2002